Title:
COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE, CONTAINING, AS ACTIVE INGREDIENT, TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/153794
Kind Code:
A1
Abstract:
The present invention relates to a composition for preventing or treating inflammatory bowel disease, containing, as an active ingredient, taurodeoxycholic acid or a pharmaceutically acceptable salt thereof. Particularly, it has been ascertained that the clinical symptoms and histopathological symptoms caused by inflammatory bowel disease are alleviated using a salt of taurodeoxycholic acid and the increase in inflammatory cells in the intestine and the production of pro-inflammatory cytokines are suppressed, and thus taurodeoxycholic acid and a pharmaceutically acceptable salt thereof can be used as an active ingredient of a composition for preventing or treating inflammatory bowel disease.
More Like This:
Inventors:
SEONG SEUNG-YONG (KR)
SEO SANG-UK (KR)
MUNKHBILEG BOLORMAA (KR)
SEO SANG-UK (KR)
MUNKHBILEG BOLORMAA (KR)
Application Number:
PCT/KR2020/001179
Publication Date:
July 30, 2020
Filing Date:
January 23, 2020
Export Citation:
Assignee:
SEOUL NAT UNIV R&DB FOUNDATION (KR)
International Classes:
A61K31/575; A23L33/10; A61P1/00; A61P29/00
Foreign References:
| US20170196895A1 | 2017-07-13 |
Other References:
JIAO HE; JINRU LIANG; SHA ZHU; WENNA ZHAO; YONGMIN ZHANG; WENJI SUN;: "Protective effect of taurohyodeoxycholic acid from Pulvis Fellis Suis on trinitrobenzene sulfonic acid induced ulcerative colitis in mice", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 670, no. 1, 27 August 2011 (2011-08-27), pages 229 - 235, XP028312072, ISSN: 0014-2999, DOI: 10.1016/j.ejphar.2011.08.036
YANG YANG; HE JIAO; SUO YUAN; LV LE; WANG JINGJING; HUO CHUANCHUAN; ZHENG ZONGWEI; WANG ZIYE; LI JING; SUN WENJI; ZHANG YONGMIN: "Anti-inflammatory effect of taurocholate on TNBS-induced ulcerative colitis in mice", BIOMEDICINE & PHARMACOTHERAPY, vol. 81, 28 April 2016 (2016-04-28), pages 424 - 430, XP029566187, ISSN: 0753-3322, DOI: 10.1016/j.biopha.2016.04.037
MÜHLBAUER M., ALLARD B., BOSSERHOFF A. K., KIESSLING S., HERFARTH H., ROGLER G., SCHÖLMERICH J., JOBIN C., HELLERBRAND C.: "Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappaB signal transduction and IL -8 gene expression in colonic epithelial cells", AMERICAN JOURNAL OF PHYSIOLOGY- GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol. 286, no. 6, 15 January 2003 (2003-01-15), pages G1000 - G1008, XP055804674, ISSN: 0193-1857, DOI: 10.1152/ajpgi.00338.2003
LIEN VAN DEN BOSSCHE, DANIEL BORSBOOM, SARAH DEVRIESE, SOPHIE VAN WELDEN, TOM HOLVOET, LINDSEY DEVISSCHER, PIETER HINDRYCKX, MARTI: "Tauroursodeoxycholic acid protects bile acid homeostasis under inflammatory conditions and dampens Crohn ' s disease-like ileitis", LABORATORY INVESTIGATION, vol. 97, no. 5, 1 May 2017 (2017-05-01), pages 519 - 529, XP055726994, ISSN: 0023-6837, DOI: 10.1038/labinvest.2017.6
SILVIO D.CLAUDIO F.: "Ulcerative Colitis, New England", JOURNAL OF MEDICINE 2011., vol. 365, 2011, pages 1713 - 25
KAPLAN, G.G.: "The global burden of IBD: from 2015 to 2025. Nature reviews", GASTROENTEROLOGY HEPATOLOGY, vol. 12, no. 12, 2015, pages 720 - 7
KIRSNER, J. B.: "Historical aspects of inflammatory bowel disease", J. CLINICAL GASTROENTEROLOGY, vol. 10, 1988, pages 286 - 297
GEREMIA, A. ET AL.: "Autoimmunity Reviews Innate and adaptive immunity in inflammatory bowel disease", AUTOIMMUNITY REVIEWS, vol. 13, no. 1, 2014, pages 3 - 10
FOURNIER, B.M.PARKOS, C.A., THE ROLE OF NEUTROPHILS DURING INTESTINAL INFLAMMATION., vol. 5, no. 4, 2012, pages 354 - 366
BAARS, A. ET AL., THE GUT MICROBIOTA AS A THERAPEUTIC TARGET IN IBD AND METABOLIC DISEASE: A ROLE FOR THE BILE ACID RECEPTORS FXR AND TGR5., 2015, pages 641 - 666
STROBER WFUSS IJ.: "2011 Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases", GASTROENTEROLOGY, vol. 140, 2011, pages 1756 - 1767
KLEIN, AELIAKIM, R.: "Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease", PHARMACEUTICALS, vol. 3, no. 4, 2010, pages 1084 - 1092
SALES-CAMPOS, H. ET AL.: "Classical and recent advances in the treatment of inflammatory bowel diseases", BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, vol. 48, no. 2, 2015, pages 96 - 107
RUSSELL DW: "The enzymes, regulation, and genetics of bile acid synthesis", ANNU. REV. BIOCHEM., vol. 72, 2003, pages 137 - 74
See also references of EP 3915566A4
YANG YANG; HE JIAO; SUO YUAN; LV LE; WANG JINGJING; HUO CHUANCHUAN; ZHENG ZONGWEI; WANG ZIYE; LI JING; SUN WENJI; ZHANG YONGMIN: "Anti-inflammatory effect of taurocholate on TNBS-induced ulcerative colitis in mice", BIOMEDICINE & PHARMACOTHERAPY, vol. 81, 28 April 2016 (2016-04-28), pages 424 - 430, XP029566187, ISSN: 0753-3322, DOI: 10.1016/j.biopha.2016.04.037
MÜHLBAUER M., ALLARD B., BOSSERHOFF A. K., KIESSLING S., HERFARTH H., ROGLER G., SCHÖLMERICH J., JOBIN C., HELLERBRAND C.: "Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappaB signal transduction and IL -8 gene expression in colonic epithelial cells", AMERICAN JOURNAL OF PHYSIOLOGY- GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol. 286, no. 6, 15 January 2003 (2003-01-15), pages G1000 - G1008, XP055804674, ISSN: 0193-1857, DOI: 10.1152/ajpgi.00338.2003
LIEN VAN DEN BOSSCHE, DANIEL BORSBOOM, SARAH DEVRIESE, SOPHIE VAN WELDEN, TOM HOLVOET, LINDSEY DEVISSCHER, PIETER HINDRYCKX, MARTI: "Tauroursodeoxycholic acid protects bile acid homeostasis under inflammatory conditions and dampens Crohn ' s disease-like ileitis", LABORATORY INVESTIGATION, vol. 97, no. 5, 1 May 2017 (2017-05-01), pages 519 - 529, XP055726994, ISSN: 0023-6837, DOI: 10.1038/labinvest.2017.6
SILVIO D.CLAUDIO F.: "Ulcerative Colitis, New England", JOURNAL OF MEDICINE 2011., vol. 365, 2011, pages 1713 - 25
KAPLAN, G.G.: "The global burden of IBD: from 2015 to 2025. Nature reviews", GASTROENTEROLOGY HEPATOLOGY, vol. 12, no. 12, 2015, pages 720 - 7
KIRSNER, J. B.: "Historical aspects of inflammatory bowel disease", J. CLINICAL GASTROENTEROLOGY, vol. 10, 1988, pages 286 - 297
GEREMIA, A. ET AL.: "Autoimmunity Reviews Innate and adaptive immunity in inflammatory bowel disease", AUTOIMMUNITY REVIEWS, vol. 13, no. 1, 2014, pages 3 - 10
FOURNIER, B.M.PARKOS, C.A., THE ROLE OF NEUTROPHILS DURING INTESTINAL INFLAMMATION., vol. 5, no. 4, 2012, pages 354 - 366
BAARS, A. ET AL., THE GUT MICROBIOTA AS A THERAPEUTIC TARGET IN IBD AND METABOLIC DISEASE: A ROLE FOR THE BILE ACID RECEPTORS FXR AND TGR5., 2015, pages 641 - 666
STROBER WFUSS IJ.: "2011 Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases", GASTROENTEROLOGY, vol. 140, 2011, pages 1756 - 1767
KLEIN, AELIAKIM, R.: "Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease", PHARMACEUTICALS, vol. 3, no. 4, 2010, pages 1084 - 1092
SALES-CAMPOS, H. ET AL.: "Classical and recent advances in the treatment of inflammatory bowel diseases", BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, vol. 48, no. 2, 2015, pages 96 - 107
RUSSELL DW: "The enzymes, regulation, and genetics of bile acid synthesis", ANNU. REV. BIOCHEM., vol. 72, 2003, pages 137 - 74
See also references of EP 3915566A4
Attorney, Agent or Firm:
KIM, Bo-min (KR)
Download PDF: